Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: Connection refused in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa emc

besponsa emc

Перейти к контенту

Главное меню:

Разное
besponsa emc
BESPONSA 1 mg powder for concentrate for solution for , Package leaflet: Information for the user BESPONSA 1 mg , Besponsa | Pfizer UK, Inotuzumab ozogamicin - Wikipedia, EMCS - The UK's Leading Independent Alarm Receiving Centre, green bags | Evidence search | NICE, EMCS, , .
For patient-reported outcomes, most functioning and symptom scores were in favour of BESPONSA compared to Investigator's choice of chemotherapy. Patient-reported outcomes measured using the European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30), were significantly better for BESPONSA by estimated mean postbaseline scores (BESPONSA and Investigator's choice of chemotherapy, respectively) for role functioning (64.7 versus 53.4, improvement grade small), physical functioning (75.0 versus 68.1, improvement grade small), social functioning (68.1 versus 59.8, improvement grade medium), and appetite loss (17.6 versus 26.3, improvement grade small) compared to Investigator's choice of chemotherapy. There was a trend in favour of BESPONSA, improvement grade small, for estimated mean postbaseline scores (BESPONSA and Investigator's choice, respectively) in global health status/Quality of Life (QoL) (62.1 versus 57.8), cognitive functioning (85.3 versus 82.5), dyspnoea (14.7 versus 19.4), diarrhoea (5.9 versus 8.9), fatigue (35.0 versus 39.4). There was a trend in favour of BESPONSA for estimated mean postbaseline scores from the EuroQoL 5 Dimension (EQ-5D) questionnaire, (BESPONSA and Investigator's choice of chemotherapy, respectively) for the EQ-5D index (0.80 versus 0.76, minimally important difference for cancer = 0.06).. BESPONSA 1 mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC) by Pfizer Limited BESPONSA 1 mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (eMC). Page 1 of 10 Package leaflet: Information for the user BESPONSA 1 mg powder for concentrate for solution for infusion inotuzumab ozogamicin.
Besponsa (inotuzumab ozogamicin) For more information on this product please visit the electronic Medicines Compendium (eMC) This medicine is subject to additional monitoring.. Inotuzumab ozogamicin (trade name Besponsa) is an antibody-drug conjugate used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). [1] [2] The medication consists of the humanized monoclonal antibody against CD22 (inotuzumab), linked to a cytotoxic agent from the class of calicheamicins called ozogamicin.. "Peace of mind for businesses and homeowners” Welcome to EMCS. We are unique in being the UK’s only truly independent Alarm Receiving Centre.. BESPONSA 1 mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (eMC) Source: electronic Medicines Compendium - eMC This is just the first eMC Summary of Product Characteristics from your search.. Like most websites, this one uses cookies. Cookies help us to improve the visitor experience to our website. By continuing to browse the site you are agreeing to our use of cookies.. .
 
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню